Vanda said a U.S. Food and Drug Administration advisory committee voted to approve the company’s flagship drug, tasimelteon, a potential treatment for Non-24-Hour Disorder. Tasimelteon, which has the proposed tradename Hetlioz, is currently under priority review by the FDA, which will make a final decision on approving the drug in January. Vanda’s shares jumped 13% to $14.73 in premarket trading.

Kimberly-Clark is mulling a spinoff of its health-care business, potentially unloading a division that generates about $1.6 billion in annual sales but represents the consumer-products giant’s smallest business. Investors cheered the news, sending shares up 3% to $113 in premarket trading.

Baxter International Inc. and Cell Therapeutics Inc. unveiled an exclusive licensing agreement to develop and commercialize pacritinib, which is currently in Phase III development to treat a chronic bone marrow disorder. Shares climbed 21% to $2.12 premarket.

T-Mobile US Inc.'s offering of about 66.2 million shares priced at a 2% discount to the wireless carrier’s closing price. The offering priced at $25 a share and is expected to generate about $1.6 billion in proceeds, T-Mobile disclosed late Thursday. Shares were off 2.5% at $24.89 premarket.

Agilent Technologies Inc.'s fiscal fourth-quarter earnings fell 50% as continued weakness in its electronic measurement business that the company is in the process of spinning off continued to weigh on the diversified testing-equipment maker’s revenue. The company’s adjusted profit topped expectations.

Applied Materials Inc. swung to fiscal fourth-quarter profit on double-digit revenue growth and stronger margins. The company, which supplies costly machines that help turn silicon wafers into computer chips, also gave a mostly cautious outlook for the current quarter.

Activist investor Carl Icahn reported an increased holding in Navistar International Corp. as of Sept. 30, according to a regulatory filing Thursday.

Nordstrom Inc.'s fiscal third-quarter profit slid 6.2% as the high-end retailer’s sales growth was tempered by the absence of a key sale event that was held earlier in the year, while overhead expenses jumped.